LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.55
−9.36%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.74
From 52W high−66.45%
Volume188240.00
Market cap$19.82M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$1.74
From 52W high
−66.45%
Volume
188240.00
Market cap
$19.82M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.7x
P/E (TTM)
—
RSI (14)
31.6
MomentumView details →
1D Return
−9.36%
YTD Return
−43.56%
SummaryUpdated Jun 1, 2026
Lantern Pharma Inc. (NASDAQ:LTRN) is a clinical-stage biotechnology company founded in 2013 and headquartered in Dallas, Texas. The company went public in June 2020 and has positioned itself at the intersection of artificial intelligence and cancer drug development. Lantern Pharma focuses on using AI, machine learning, and genomic data to streamline and accelerate the traditionally lengthy and expensive drug development process, with a particular emphasis on precision oncology treatments.
Similar companies
Latest newsMore news →
Lantern Pharma announced it will host a live webinar on September 23, 2026 to present the business model, development roadmap, and value proposition of Open-Medicine AI, its wholly owned subsidiary building a multi-agentic AI platform for end-to-end therapeutic development.3d agoLantern Pharma reported its financial results for the second quarter of 2026 and provided a business update.37d agoLantern Pharma established Open-Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform.48d ago